Placenta extract shows promise for liver disease in early trial
NCT ID NCT05532124
First seen Feb 25, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tested a medicine called LAENNEC, made from human placenta, in 49 adults with chronic liver disease (from alcohol or fatty liver). The goal was to check safety and find the best dose by measuring liver enzyme (ALT) levels. It was a Phase 2 trial, meaning it's an early step to see if the treatment works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanyang University Hospital.
Seoul, South Korea
-
Keimyung university dongsan medical center
Daegu, South Korea
-
Korea university guro hospital
Seoul, South Korea
-
Severance hospital
Seoul, South Korea
-
Soonchunhyang university hospital
Seoul, South Korea
-
Wonju severance christian hospital
Wŏnju, South Korea
-
Yeungnam university
Daegu, South Korea
Conditions
Explore the condition pages connected to this study.